Imagine being able to print a live organ as you are used to do with a photography. Sounds distant, but some progress is happening in the 3D printing field, which has come with an innovation to respond to this growing demand and to solve some problems they themselves have being facing: costs of manufacturing, time efficiency and consumer delivery.
With the techniques of Bioprint 3D, this technology is revolutionizing the healthcare industry, with the production of living tissue, blood vessels and organs potentially for medical purposes. By this time, it has already been made clear that personalization is the trend that highlights the most nowadays among different sectors and 3D printing is one of them.
Bioprint 3D has revolutionized the global healthcare scenario and has opened an enormous door for insurers. Asia and the USA are clearly the most advanced in general with this technology, due to an increasing in Research & Development, government support and tax incentives. Three of the more than a hundred examples that are implementing this cutting-edge technology are companies like: Allevi, Cyfuse Biomedical K.K. and Pandorum Technologies, who are leading to medical advancements and improved quality of life in their own markets.
From NTT DATA we visualize bioprinting 3D as a turning point for both the healthcare and the insurance industry. It leverages a new portfolio possibility, with new policies and liabilities to be covered by insurers, and so it is a chance that these actors must take advantage of, proactively collaborating with these innovative companies to ensure that not only technologies, but also research, development and commercialization are viable in today’s market.
It is a chance for insurers to proactively collaborate with innovative companies to ensure that not only technologies, but also research, development and commercialization are viable in today’s market.
Jordi Fontestad, NTT DATA EMEAL Health Director